

POT-4

Cat. No.:	HY-P3204	
CAS No.:	934461-40-2	
Molecular Formula:	$C_{72}H_{102}N_{22}O_{18}S_2$	
Molecular Weight:	1627.85	Ac-ICV{Trp(Me)}QDWGAHRCT-NH ₂ (Disulfide bridge:Cys ₂ -Cys ₁₂)
Sequence Shortening:	Ac-ICV{Trp(Me)}QDWGAHRCT-NH ₂ (Disulfide bridge:Cys ₂ -Cys ₁₂)	
Target:	Complement System	
Pathway:	Immunology/Inflammation	
Storage:	Sealed storage, away from moisture	
	Powder	-80°C 2 years -20°C 1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (61.43 mM; Need ultrasonic)				
	H ₂ O : 50 mg/mL (30.72 mM; Need ultrasonic)				
	Preparing Stock Solutions	<div>Solvent Concentration</div> <div>Mass</div>	1 mg	5 mg	10 mg
		1 mM	0.6143 mL	3.0715 mL	6.1431 mL
		5 mM	0.1229 mL	0.6143 mL	1.2286 mL
		10 mM	0.0614 mL	0.3072 mL	0.6143 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (1.54 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (1.54 mM); Suspended solution; Need ultrasonic				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil				
	Solubility: ≥ 2.5 mg/mL (1.54 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research ^{[1][2]}
In Vitro	A derivative of compstatin, a potent C3 inhibitor, POT-4 is a cyclic peptide that exhibits binding activity to C3, preventing cleavage to its active fragments C3a and C3b ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. S. Kaushal, et al. Complement C3 inhibitor POT-4: Clinical Safety of Intravitreal Administration. ARVO Annual Meeting Abstract, 2009 Apr.
- [2]. Robyn Troutbeck, et al. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Exp Ophthalmol. Jan-Feb 2012;40(1):18-26.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA